BFC
DFTX

Bedel Financial Consulting’s Definium Therapeutics DFTX Stock Holding History

Bedel Financial Consulting’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1
Closed – – 1029
2021
Q4 		$0 Hold
1
– – ﹤0.01% 1050
2021
Q3 		$0 Hold
1
– – ﹤0.01% 1010
2021
Q2 		$0 Buy
+1
New +$52 ﹤0.01% 995

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $174B AUM 30.96% 1-Year Est. Return

Bedel Financial Consulting's DFTX Position: Q1 2022 in Review

Bedel Financial Consulting sold out of Definium Therapeutics (DFTX) in Q1 2022, closing a stake of 1 share.

Bedel Financial Consulting first reported a position in DFTX in Q2 2021 and held it in 3 quarters. The position peaked at $0 in Q4 2021. 159 funds tracked by Wall St. Rank hold DFTX as of Q1 2022.

  • Bedel Financial Consulting reported no remaining Definium Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Bedel Financial Consulting sold 1 Definium Therapeutics share in Q1 2022.
  • Bedel Financial Consulting first reported a position in Definium Therapeutics in Q2 2021 and held it in 3 quarters.
  • Bedel Financial Consulting's Definium Therapeutics position peaked at $0 in Q4 2021.
  • 159 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2022.

Based on Bedel Financial Consulting's 13F filing for Q1 2022, filed 19 Apr 2022.